Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
LUMMICAR STUDY 2
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
- NCT03915184 ↗
- Active, not recruiting
- CARsgen Therapeutics Co., Ltd.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- zevor-cel
- Arms
- CAR-BCMA T Cells · Experimental
- Enrollment
- 105 (estimated)
- Primary outcomes
- Incidence of Treatment Related adverse events (AEs)
- Identification of Maximum Tolerated Dose (MTD)
- Objective response rate
- Sponsor
- CARsgen Therapeutics Co., Ltd.
- Start
- Sep 25, 2019
- Primary completion
- Dec 31, 2024 (estimated)
- Results posted
- No
- Registry record
- NCT03915184 · updated Dec 19, 2023